^
BIOMARKER:

BCR-ABL1 F317L

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
BCR-ABL1 F317L
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
CML
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 F317L
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
ALL
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 F317L
ALL
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
CML
dasatinib + imatinib
Resistant: C2 – Inclusion Criteria
BCR-ABL1 F317L
CML
imatinib
Resistant: C3 – Early Trials